Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Bitcoin Sell-Side Risk Ratio Returns to Historic Buy Zone

Bitcoin Sell-Side Risk Ratio Returns to Historic Buy Zone

CoinpediaCoinpedia2026/07/01 18:31
By:Coinpedia
Story Highlights
  • Bitcoin Sell-Side Risk Ratio has fallen back near the 1% low-risk zone.

  • Similar historical readings preceded major recoveries since 2016.

  • MVRV and NUPL indicators are also signaling undervaluation conditions.

The market loves panic near bottoms and confidence near tops. The latest Bitcoin Sell-Side Risk Ratio reading seems determined to remind traders of that uncomfortable truth once again.

The adjusted metric has now fallen back toward the low-risk zone, sitting around 1% on the logarithmic scale, firmly inside what historical data classifies as the blue accumulation territory. That’s usually where sellers run out of ammunition.

When Selling Pressure Starts To Disappear

The Sell-Side Risk Ratio measures realized profits and losses relative to realized market capitalization. In simpler terms, it tracks how aggressively market participants are cashing out.

When the ratio spikes, holders are distributing coins into strength and locking in gains.

When it collapses toward current levels, very little profit-taking remains. There’s simply less incentive to sell. Markets have seen this movie before.

Previous Signals Arrived Before Major Recoveries

As per analyst RugaResearch, historical data since 2016 shows similar readings appeared during late 2016, early 2019, March 2020, late 2022, and late 2023.

Each period eventually evolved into significant recovery phases or major bull market expansions. The common ingredient wasn’t excitement. It was exhaustion. Selling dried up before demand returned.

Bitcoin Sell-Side Risk Ratio Returns to Historic Buy Zone image 0

Multiple Valuation Metrics Flash Together Again

The signal isn’t appearing in isolation either. MVRV continues compressing toward realized price while NUPL remains in capitulation territory. The combination places several long-term valuation indicators in statistically cheap zones simultaneously.

That doesn’t guarantee the market has found its exact bottom. Markets rarely offer such generosity.

The possibility of deeper declines remains firmly on the table. Still, history suggests accumulation zones aren’t identified by comfort or certainty. They’re identified by apathy, disbelief, and a lack of willing sellers.

The current Bitcoin Sell-Side Risk Ratio suggests the market may be entering exactly that kind of environment.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales